Brainomix Showcases Growing Evidence for Its Novel AI-Based Imaging Biomarkers in Lung Fibrosis
Brainomix Showcases Growing Evidence for Its Novel AI-Based Imaging Biomarkers in Lung Fibrosis
- The company unveiled a series of new studies highlighting the prognostic value of its imaging biomarkers in patients with fibrotic lung disease
- The studies reflect the company's expanding Life Science partnerships and academic collaborations with luminary research centers in the lung space
- 該公司公佈了一系列新研究，重點介紹了其成像生物標誌物對纖維化肺病患者的預後價值
- 這些研究反映了該公司不斷擴大的生命科學合作伙伴關係以及與肺部領域傑出研究中心的學術合作
OXFORD, England and CHICAGO, May 22, 2024 /PRNewswire/ -- Brainomix, a pioneer in artificial intelligence (AI) imaging solutions to enable precision medicine, announced a series of new studies that were presented this week at the American Thoracic Society (ATS) Conference in San Diego.
英國牛津和芝加哥，2024年5月22日 /PRNewswire/--實現精準醫療的人工智能（AI）成像解決方案的先驅Brainomix宣佈了一系列新研究，這些研究將於本週在聖地亞哥舉行的美國胸科學會（ATS）會議上發表。
"The studies presented this week at ATS are a reflection of our continual focus on scientific excellence and academic collaboration with both world-class institutions as well as with Life Science partners," noted Dr Michalis Papadakis, CEO and Co-Founder of Brainomix. "The results highlight the prognostic value of our novel Brainomix lung imaging biomarkers to accurately predict disease progression in Idiopathic Pulmonary Fibrosis (IPF) and non-IPF patients."
指出：“本週在ATS上發表的研究反映了我們對卓越科學的持續關注以及與世界一流機構以及生命科學合作伙伴的學術合作。” 米哈利斯·帕帕達基斯博士，Brainomix 首席執行官兼聯合創始人。“研究結果突顯了我們的新型Brainomix肺部成像生物標誌物的預後價值，可準確預測特發性肺纖維化（IPF）和非IPF患者的疾病進展。”
Key abstracts accepted and presented at ATS included:
在 ATS 上接受和提交的主要摘要包括：
- "Diagnosis and the role of imaging biomarkers in predicting outcomes for patients with Non-IPF Fibrotic ILD," was a research collaboration with Heidelberg University in which a cohort of 347 patients with non-IPF over a 10-year period was analyzed with Brainomix's novel lung imaging biomarker, the weighted reticulovascular score (WRVS). The results indicated WRVS was a strong predictor for death and independent risk factor for 10% Forced Vital Capacity (FVC) decline. "This study has demonstrated the prognostic value of the Brainomix WRVS imaging biomarker, which can be a valuable predictor of progressive disease in this cohort of patients with fibrotic non-IPF ILD," noted Prof Dr Michael Kreuter, Director for the Lung Center Mainz.
- "Differences in lung biomarker scores between treatment groups in post-hoc analysis of the ATLAS inhaled pirfenidone solution (AP01) for IPF clinical trials" was a research collaboration with Avalyn Pharma, a Seattle-based clinical-stage biopharmaceutical company. Brainomix lung imaging biomarkers (including WRVS) were studied in a post-hoc analysis of Avalyn's phase 1b clinical trial of inhaled pirfenidone (ATLAS study) in patients with IPF, with results showing that WRVS was associated with risk of future IPF progression in the low-dose pirfenidone group. "This research can assist in the optimisation of AI imaging tools to enrich clinical trials for progressive patients, to facilitate matching treatment arms and further explore novel trial end points," Dr Peter George, Senior Medical Director at Brainomix and Clinical Lead for ILD at Royal Brompton Hospital in London.
- "Lung CT biomarkers can stratify patients at risk of Idiopathic Pulmonary Fibrosis progression at 52 weeks: post-hoc analysis from a randomised control trial" was a research collaboration with AstraZeneca using the Phase 2 IPF tralokinumab clinical trial. WRVS was shown to accurately predict patients at baseline at risk of 52-week FVC decline. "These data suggests that our WRVS biomarker may enable more sophisticated design of future clinical trials," said Ross Stewart, Senior Business Development Manager, Pharma Partnerships, at Brainomix.
- “診斷和成像生物標誌物在預測非IPF纖維化ILD患者預後中的作用”，是與海德堡大學的一項研究合作，其中使用Brainomix的新型肺部成像生物標誌物加權網狀血管評分（WRVS）對10年內347名非IPF患者的隊列進行了分析。結果表明，WRVS是死亡的有力預測指標，也是強制生命容量（FVC）下降10％的獨立危險因素。指出：“這項研究證明了Brainomix WRVS成像生物標誌物的預後價值，該標誌物可以作爲該組纖維化非IPF ILD患者進行性疾病的寶貴預測指標。” 邁克爾·克羅伊特博士教授，美因茲肺部中心主任。
- “在IPF臨床試驗的ATLAS吸入式吡非尼酮溶液（AP01）事後分析中，治療組之間肺部生物標誌物評分的差異” 是與總部位於西雅圖的臨床階段生物製藥公司Avalyn Pharma的研究合作。對Avalyn針對IPF患者的吸入性吡非尼酮的1b期臨床試驗（ATLAS研究）的事後分析對Brainomix肺部成像生物標誌物（包括WRVS）進行了研究，結果表明WRVS與低劑量吡非尼酮組未來IPF進展的風險有關。“這項研究可以幫助優化人工智能成像工具，以豐富進展患者的臨床試驗，促進匹配治療組並進一步探索新的試驗終點，” 彼得·喬治博士，Brainomix高級醫學董事兼倫敦皇家布朗普頓醫院ILD臨床負責人。
- “肺部CT生物標誌物可以在52周時對有特發性肺纖維化進展風險的患者進行分層：一項隨機對照試驗的事後分析” 是與阿斯利康使用2期IPF tralokinumab臨床試驗進行的一項研究合作。事實證明，WRVS可以準確預測處於基線時面臨52周FVC下降風險的患者。他說：“這些數據表明，我們的WRVS生物標誌物可以爲未來的臨床試驗提供更復雜的設計。” 羅斯斯圖爾特，Brainomix製藥合作伙伴關係高級業務發展經理。
About Brainomix
關於 Brainomix
Brainomix specializes in the creation of AI-powered software solutions to enable precision medicine for better treatment decisions in stroke and lung fibrosis. With origins as a spin-out from the University of Oxford, Brainomix is an expanding commercial-stage company with offices in the UK, Ireland and the USA, and operations in more than 30 countries. A private company, backed by leading healthtech investors, Brainomix has innovated award-winning imaging biomarkers and software solutions that have been clinically adopted in hundreds of hospitals worldwide. Its first product, the Brainomix 360 stroke platform, provides clinicians with the most comprehensive stroke imaging solution, driving increased treatment rates and improving functional independence for patients.
Brainomix 專門開發人工智能驅動的軟件解決方案，以實現精準醫療，從而更好地做出中風和肺纖維化的治療決策。Brainomix 起源於牛津大學，是一家不斷擴張的商業階段公司，在英國、愛爾蘭和美國設有辦事處，業務遍及30多個國家。Brainomix是一傢俬營公司，由領先的健康科技投資者提供支持，創新了屢獲殊榮的成像生物標誌物和軟件解決方案，已被全球數百家醫院臨床採用。其首款產品Brainomix 360中風平台爲臨床醫生提供了最全面的中風成像解決方案，從而提高了治療率並改善了患者的功能獨立性。
To learn more about Brainomix and its technology visit , and follow us on Twitter, LinkedIn and Facebook.
要了解有關 Brainomix 及其技術的更多信息，請訪問 ，然後繼續關注我們 推特， 領英 和 Facebook。
Contacts
聯繫人
Jeff Wyrtzen, Chief Marketing & Business Development Officer
[email protected]
M +44 (0)7927 164210
T +44 (0)1865 582730
Jeff Wyrtzen，首席營銷和業務發展官
[電子郵件保護]
M +44 (0) 7927 164210
電話 +44 (0) 1865 582730
Media enquiries
媒體查詢
Charles Consultants
Sue Charles
[email protected]
M +44 (0)7968 726585
查爾斯顧問
蘇查爾斯
[電子郵件保護]
M +44 (0) 7968 726585
Logo -
徽標-
SOURCE Brainomix
來源 Brainomix
譯文內容由第三人軟體翻譯。